The expression of Claudin 1 correlates with β-catenin and is a prognostic factor of poor outcome in gastric cancer

Huang,Jie; Li,Jianfang; Qu,Ying; Zhang,Jianian; Zhang,Li; Chen,Xuehua; Liu,Bingya; Zhu,Zhenggang

doi:10.3892/ijo.2014.2298

The expression of Claudin 1 correlates with β-catenin and is a prognostic factor of poor outcome in gastric cancer

Authors:
- Jie Huang
- Jianfang Li
- Ying Qu
- Jianian Zhang
- Li Zhang
- Xuehua Chen
- Bingya Liu
- Zhenggang Zhu
View Affiliations

Affiliations: Department of Surgery, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, P.R. China, Department of Surgery, Department of Obstetrics and Gynecology, Women's Cancer Institute, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
Published online on: February 12, 2014 https://doi.org/10.3892/ijo.2014.2298
Pages: 1293-1301

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Claudin 1 is one of the tight junction proteins, which are critical in the maintenance of epithelial integrity. Aberrant regulation of CLDN1 and its correlation with β-catenin have been discovered in malignant tumors. The present study aimed to investigate the expression profile and clinical relevance of CLDN1 and β-catenin. The protein levels of CLDN1 and β-catenin were examined using immunohistochemical staining. The characteristics of expression profile and prognostic value were analyzed using Pearson's χ2 test and Kaplan-Meier analysis, respectively. β-catenin overexpression and knockdown were used to investigate its role in regulating CLDN1 expression. We showed that CLDN1 was overexpressed in intestinal-type, presence of lymph node metastasis, higher TNM stage in gastric cancer patients and correlated with decreased overall survival. The characteristics of CLDN1 expression were associated with that of β-catenin. CLDN1 and β-catenin showed similar prognostic value in intestinal-type gastric cancers. β-catenin knockdown and overexpression in cell models revealed a positive relation between CLDN1 and β-catenin. Our study demonstrated that CLDN1 is a biomarker for intestinal-type gastric cancer with shorter survival. The expression of CLDN1 was strongly associated with β-catenin in gastric cancer patients and a gastric cancer cell model.

View Figures

View References

1.	Brenner H, Rothenbacher D and Arndt V: Epidemiology of stomach cancer. Methods Mol Biol. 472:467–477. 2009. View Article : Google Scholar
2.	Du C, Zhou Y, Cai H, Zhao G, Fu H and Shi YQ: Poor prognostic factors in patients with stage I gastric cancer according to the seventh edition TNM classification: a comparative analysis of three subgroups. J Surg Oncol. 105:323–328. 2012. View Article : Google Scholar : PubMed/NCBI
3.	Lazar D, Taban S, Sporea I, et al: Gastric cancer: correlation between clinicopathological factors and survival of patients (III). Rom J Morphol Embryol. 50:369–379. 2009.PubMed/NCBI
4.	Lazar D, Taban S, Sporea I, et al: Gastric cancer: correlation between clinicopathological factors and survival of patients. II. Rom J Morphol Embryol. 50:185–194. 2009.PubMed/NCBI
5.	Tsukita S and Furuse M: Claudin-based barrier in simple and stratified cellular sheets. Curr Opin Cell Biol. 14:531–536. 2002. View Article : Google Scholar : PubMed/NCBI
6.	Tobioka H, Isomura H, Kokai Y, Tokunaga Y, Yamaguchi J and Sawada N: Occludin expression decreases with the progression of human endometrial carcinoma. Hum Pathol. 35:159–164. 2004. View Article : Google Scholar : PubMed/NCBI
7.	Pope JL, Bhat AA, Sharma A, et al: Claudin-1 regulates intestinal epithelial homeostasis through the modulation of Notch-signalling. Gut. Jun 13–2013.Epub ahead of print.
8.	Noda S, Tanabe S and Suzuki T: Naringenin enhances intestinal barrier function through the expression and cytoskeletal association of tight junction proteins in Caco-2 cells. Mol Nutr Food Res. 57:2019–2028. 2013. View Article : Google Scholar
9.	Iraha A, Chinen H, Hokama A, et al: Fucoidan enhances intestinal barrier function by upregulating the expression of claudin-1. World J Gastroenterol. 19:5500–5507. 2013. View Article : Google Scholar : PubMed/NCBI
10.	Myal Y, Leygue E and Blanchard AA: Claudin 1 in breast tumorigenesis: revelation of a possible novel ‘claudin high’ subset of breast cancers. J Biomed Biotechnol. 2010:9568972010.PubMed/NCBI
11.	Blanchard AA, Ma X, Dueck KJ, et al: Claudin 1 expression in basal-like breast cancer is related to patient age. BMC Cancer. 13:2682013. View Article : Google Scholar : PubMed/NCBI
12.	Chang TL, Ito K, Ko TK, et al: Claudin-1 has tumor suppressive activity and is a direct target of RUNX3 in gastric epithelial cells. Gastroenterology. 138:255–265. 2010. View Article : Google Scholar : PubMed/NCBI
13.	Qin W, Ren Q, Liu T, Huang Y and Wang J: MicroRNA-155 is a novel suppressor of ovarian cancer-initiating cells that targets CLDN1. FEBS Lett. 587:1434–1439. 2013. View Article : Google Scholar : PubMed/NCBI
14.	Chao YC, Pan SH, Yang SC, et al: Claudin-1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma. Am J Respir Crit Care Med. 179:123–133. 2009. View Article : Google Scholar
15.	Dhawan P, Singh AB, Deane NG, et al: Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J Clin Invest. 115:1765–1776. 2005. View Article : Google Scholar : PubMed/NCBI
16.	Kinugasa T, Akagi Y, Ochi T, et al: Increased claudin-1 protein expression in hepatic metastatic lesions of colorectal cancer. Anticancer Res. 32:2309–2314. 2012.PubMed/NCBI
17.	Ersoz S, Mungan S, Cobanoglu U, Turgutalp H and Ozoran Y: Prognostic importance of Claudin-1 and Claudin-4 expression in colon carcinomas. Pathol Res Pract. 207:285–289. 2011. View Article : Google Scholar : PubMed/NCBI
18.	Morohashi S, Kusumi T, Sato F, et al: Decreased expression of claudin-1 correlates with recurrence status in breast cancer. Int J Mol Med. 20:139–143. 2007.PubMed/NCBI
19.	Zhang Z, Wang A, Sun B, Zhan Z, Chen K and Wang C: Expression of CLDN1 and CLDN10 in lung adenocarcinoma in situ and invasive lepidic predominant adenocarcinoma. J Cardiothorac Surg. 8:952013. View Article : Google Scholar : PubMed/NCBI
20.	Matsuda Y, Semba S, Ueda J, et al: Gastric and intestinal claudin expression at the invasive front of gastric carcinoma. Cancer Sci. 98:1014–1019. 2007. View Article : Google Scholar : PubMed/NCBI
21.	Suh Y, Yoon CH, Kim RK, et al: Claudin-1 induces epithelialmesenchymal transition through activation of the c-Abl-ERK signaling pathway in human liver cells. Oncogene. 32:4873–4882. 2013. View Article : Google Scholar : PubMed/NCBI
22.	Singh AB, Sharma A and Dhawan P: Claudin-1 expression confers resistance to anoikis in colon cancer cells in a Src-dependent manner. Carcinogenesis. 33:2538–2547. 2012. View Article : Google Scholar : PubMed/NCBI
23.	Singh AB, Sharma A, Smith JJ, et al: Claudin-1 up-regulates the repressor ZEB-1 to inhibit E-cadherin expression in colon cancer cells. Gastroenterology. 141:2140–2153. 2011. View Article : Google Scholar : PubMed/NCBI
24.	Shiozaki A, Bai XH, Shen-Tu G, et al: Claudin 1 mediates TNFalpha-induced gene expression and cell migration in human lung carcinoma cells. PLoS One. 7:e380492012. View Article : Google Scholar
25.	Di Cello F, Cope L, Li H, et al: Methylation of the claudin 1 promoter is associated with loss of expression in estrogen receptor positive breast cancer. PLoS One. 8:e686302013.PubMed/NCBI
26.	Blanchard AA, Skliris GP, Watson PH, et al: Claudins 1, 3, and 4 protein expression in ER negative breast cancer correlates with markers of the basal phenotype. Virchows Arch. 454:647–656. 2009. View Article : Google Scholar
27.	Moldvay J, Jackel M, Paska C, Soltesz I, Schaff Z and Kiss A: Distinct claudin expression profile in histologic subtypes of lung cancer. Lung Cancer. 57:159–167. 2007. View Article : Google Scholar : PubMed/NCBI
28.	Miwa N, Furuse M, Tsukita S, Niikawa N, Nakamura Y and Furukawa Y: Involvement of claudin-1 in the beta-catenin/Tcf signaling pathway and its frequent upregulation in human colorectal cancers. Oncol Res. 12:469–476. 2001. View Article : Google Scholar
29.	Bhat AA, Sharma A, Pope J, et al: Caudal homeobox protein Cdx-2 cooperates with Wnt pathway to regulate claudin-1 expression in colon cancer cells. PLoS One. 7:e371742012. View Article : Google Scholar : PubMed/NCBI
30.	Shiou SR, Singh AB, Moorthy K, et al: Smad4 regulates claudin-1 expression in a transforming growth factor-beta-independent manner in colon cancer cells. Cancer Res. 67:1571–1579. 2007. View Article : Google Scholar : PubMed/NCBI
31.	Sharma A, Bhat AA, Krishnan M, Singh AB and Dhawan P: Trichostatin-A modulates claudin-1 mRNA stability through the modulation of Hu antigen R and tristetraprolin in colon cancer cells. Carcinogenesis. 34:2610–2621. 2013. View Article : Google Scholar : PubMed/NCBI
32.	Krishnan M, Singh AB, Smith JJ, et al: HDAC inhibitors regulate claudin-1 expression in colon cancer cells through modulation of mRNA stability. Oncogene. 29:305–312. 2010. View Article : Google Scholar : PubMed/NCBI
33.	Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ and Levin B: bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res. 55:237–241. 1995.PubMed/NCBI
34.	Mrsny RJ, Brown GT, Gerner-Smidt K, et al: A key claudin extra-cellular loop domain is critical for epithelial barrier integrity. Am J Pathol. 172:905–915. 2008. View Article : Google Scholar : PubMed/NCBI
35.	Stebbing J, Filipovic A and Giamas G: Claudin-1 as a promoter of EMT in hepatocellular carcinoma. Oncogene. 32:4871–4872. 2013. View Article : Google Scholar : PubMed/NCBI
36.	Yoon CH, Kim MJ, Park MJ, et al: Claudin-1 acts through c-Abl-protein kinase Cdelta (PKCdelta) signaling and has a causal role in the acquisition of invasive capacity in human liver cells. J Biol Chem. 285:226–233. 2010. View Article : Google Scholar : PubMed/NCBI
37.	Zavala-Zendejas VE, Torres-Martinez AC, Salas-Morales B, Fortoul TI, Montano LF and Rendon-Huerta EP: Claudin-6, 7, or 9 overexpression in the human gastric adenocarcinoma cell line AGS increases its invasiveness, migration, and proliferation rate. Cancer Invest. 29:1–11. 2011. View Article : Google Scholar : PubMed/NCBI
38.	Soini Y, Tommola S, Helin H and Martikainen P: Claudins 1, 3, 4 and 5 in gastric carcinoma, loss of claudin expression associates with the diffuse subtype. Virchows Arch. 448:52–58. 2006. View Article : Google Scholar : PubMed/NCBI
39.	Resnick MB, Gavilanez M, Newton E, et al: Claudin expression in gastric adenocarcinomas: a tissue microarray study with prognostic correlation. Hum Pathol. 36:886–892. 2005. View Article : Google Scholar
40.	Wu YL, Zhang S, Wang GR and Chen YP: Expression transformation of claudin-1 in the process of gastric adenocarcinoma invasion. World J Gastroenterol. 14:4943–4948. 2008. View Article : Google Scholar : PubMed/NCBI
41.	Demir R, Dimmler A, Naschberger E, et al: Malignant progression of invasive tumour cells seen in hypoxia present an accumulation of beta-catenin in the nucleus at the tumour front. Exp Mol Pathol. 87:109–116. 2009. View Article : Google Scholar : PubMed/NCBI
42.	Li YP, Wu CC, Chen WT, Huang YC and Chai CY: The expression and significance of WWOX and beta-catenin in hepatocellular carcinoma. APMIS. 121:120–126. 2013. View Article : Google Scholar : PubMed/NCBI
43.	Ooi CH, Ivanova T, Wu J, et al: Oncogenic pathway combinations predict clinical prognosis in gastric cancer. PLoS Genet. 5:e10006762009. View Article : Google Scholar : PubMed/NCBI